Viking Therapeutics stock rating reiterated at Buy by BTIG on obesity drug progress
PositiveFinancial Markets

Viking Therapeutics has received a positive boost as BTIG has reiterated its Buy rating on the company's stock, highlighting promising progress in its obesity drug development. This endorsement is significant as it reflects confidence in Viking's potential to address a growing health crisis, making it an attractive investment opportunity for those looking to capitalize on advancements in the pharmaceutical sector.
— Curated by the World Pulse Now AI Editorial System






